

EudraCT number: 2021-001088-26

Sponsor Company: F. Hoffmann-La Roche Ltd

Study Title: Sakurabonsai: Clinical, Imaging and Biomarker Open-Label Study in Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab as an Intervention

The study MN42928 was planned to be conducted at European Union (EU), or European Economic Area (EEA) sites. However, no subjects were enrolled in the EU or EEA and the study ended prematurely. Consequently, study results will not be submitted.